ClinicalTrials.gg
CompletedNCT05061446Updated Oct 29, 2024Results posted

Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

A Phase 2 interventional study of Etrasimod and Etrasimod in Ulcerative Colitis, sponsored by Pfizer. Completed at 80 sites in Japan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-10-29.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing etrasimod in Colitis, Ulcerative — 3 open to participants now, 5 under way, 2 of them phase 3. etrasimod · Colitis, Ulcerative.

Enrollment
9th of 12
54 · median 195
Started
2021
with 1 other
Phase 2
6 of 12
2 open now
Registered
9th of 12
by date
Lead sponsor
6 of 12
Pfizer

Among the 12 studies testing etrasimod in Colitis, Ulcerative, this one is the 9th largest by enrollment, is one of 2 that started in 2021, is one of 6 in phase 2, and was the 9th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

3 of the 12 studies testing etrasimod in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About etrasimod

etrasimod: first FDA approval 2023 (VELSIPITY), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing etrasimod in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this Japan-only study is to assess the safety and efficacy of etrasimod at 2 doses in Japanese subjects with moderately to severely active ulcerative colitis (UC) when administered for 12 weeks.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Ulcerative Colitis
  • APD334
  • Etrasimod
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese ancestry
  • Diagnosed with ulcerative colitis (UC) ≥ 3 months prior to screening
  • Having active UC confirmed by endoscopy
  • Moderately to severely active UC

Exclusion criteria

Exclusion Criteria:

  • Severe extensive colitis
  • Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence, history of a fistula consistent with CD
  • Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Etrasimod Dose 1

    Drug: Etrasimod

  • Experimental
    Etrasimod Dose 2

    Drug: Etrasimod

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Etrasimod tablet by mouth, once daily for 12 weeks

    Also known as: APD334

  • Etrasimod tablet by mouth, once daily for 12 weeks

    Also known as: APD334

  • DrugPlacebo

    Etrasimod matching placebo tablet by mouth, once daily up to 12 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Clinical Remission at Week 12

    Clinical remission:Participants with stool frequency (SF)subscore=0(or of 1 with greater than or equal to(\>=)1 point decrease from baseline,rectal bleeding(RB)subscore=0 and endoscopic score(ES)less than or equal to(\<)=1(excluding friability).SF subscore:number of stools in 24-hours relative to normal number of stools for that participant in same period,score ranged from 0(normal number of stools) to 3(5 or more stools than normal),higher scores=more severity.RB subscore:most severe amount of blood passed per rectum in 24-hours,score ranged from 0(no blood seen)to 3(blood alone passes),higher scores=more severity.ES:reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy,score ranged from 0(normal or inactive disease) to 3(severe disease \[spontaneous bleeding,ulceration\]),higher scores=more severity.Modified Mayo score:measure disease activity for UC,score:0(normal) to 9(maximum severity),comprised subscores for SF,RB,ES.higher score=more severe disease activity.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants Who Achieved Endoscopic Improvement at Week 12

    Endoscopic improvement was defined as ES \<= 1 (excluding friability). ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]), higher scores = more severity. Modified Mayo score (MMS): measure disease activity for UC, score: 0 (normal) to 9 (maximum severity),and comprised the subscores for SF, RB, ES. Higher score = more severe disease activity.

    Time frame: Week 12

  2. Percentage of Participants Who Achieved Symptomatic Remission at Week 12

    Symptomatic remission was defined as SF sub score = 0 (or = 1 with a \>= 1 point decrease from baseline) and RB sub score = 0. SF subscore: reported number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, score ranged from 0 (normal number of stools) to 3 (5 or more stools than normal), higher scores = more severity. RB subscore: reported the most severe amount of blood passed per rectum in a 24-hour period, score ranged from 0 (no blood seen) to 3 (blood alone passes), higher scores = more severity. MMS: measure disease activity for UC, score: 0 (normal) to 9 (maximum severity), and comprised the subscores for SF, RB, ES. Higher score = more severe disease activity.

    Time frame: Week 12

  3. Percentage of Participants Who Achieved Mucosal Healing at Week 12

    Mucosal healing was defined as ES \<= 1 (excluding friability) with histologic remission defined as a Geboes index score \< 2.0). ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]), higher scores = more severity. The Geboes score grading system, was a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicated more severe disease. Modified Mayo score (MMS): measure disease activity for UC, score: 0 (normal) to 9 (maximum severity), comprised subscores for SF, RB, ES. Higher score = more severe disease activity.

    Time frame: Week 12

  4. Percentage of Participants Who Achieved Clinical Response at Week 12

    Clinical response was defined as a \>= 2-point and \>= 30 percentage (%) decrease from baseline in MMS, and a \>= 1-point decrease from baseline in RB subscore or an absolute RB subscore \<= 1. MMS: measure disease activity for UC, score: 0 (normal) to 9 (maximum severity), and comprised the subscores for SF, RB, ES. Higher score = more severe disease activity. RB subscore: reported the most severe amount of blood passed per rectum in a 24-hour period, score ranged from 0 (no blood seen) to 3 (blood alone passes), higher scores = more severity.

    Time frame: Week 12

  5. Percentage of Participants Who Achieved Endoscopic Normalization at Week 12

    Endoscopic normalization was defined as ES= 0. ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]), higher scores = more severity. MMS: measure disease activity for UC, score: 0 (normal) to 9 (maximum severity), and comprised the subscores for SF, RB, ES. Higher score = more severe disease activity.

    Time frame: Week 12

Other outcomes

  1. Number of Participants With Adverse Events According to Severity

    An adverse event was any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. An adverse event was therefore any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Severity was classified using common terminology criteria for adverse events (CTCAE), version 5.0, such as Grade 1 for mild, Grade 2 for moderate, Grade 3 for severe, Grade 4 for life-threatening, Grade 5 for death related to adverse event.

    Time frame: Day 1 of first dose of study treatment up to 4 weeks after administration of the final dose of study treatment (maximum up to 16 weeks)

07

Results

Posted Oct 29, 2024

Participant flow

A total of 54 Japanese participants with moderate to severely active ulcerative colitis (UC) were enrolled in the study.

Participant flow — Overall Study
MilestonePlaceboEtrasimod 1 mgEtrasimod 2 mg
Started181719
Completed161619
Not completed210
Withdrew: Adverse event200
Withdrew: Participant no longer available due to personal reason010

Outcome measures

PrimaryPercentage of Participants Who Achieved Clinical Remission at Week 12

Clinical remission:Participants with stool frequency (SF)subscore=0(or of 1 with greater than or equal to(\>=)1 point decrease from baseline,rectal bleeding(RB)subscore=0 and endoscopic score(ES)less than or equal to(\<)=1(excluding friability).SF subscore:number of stools in 24-hours relative to normal number of stools for that participant in same period,score ranged from 0(normal number of stools) to 3(5 or more stools than normal),higher scores=more severity.RB subscore:most severe amount of blood passed per rectum in 24-hours,score ranged from 0(no blood seen)to 3(blood alone passes),higher scores=more severity.ES:reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy,score ranged from 0(normal or inactive disease) to 3(severe disease \[spontaneous bleeding,ulceration\]),higher scores=more severity.Modified Mayo score:measure disease activity for UC,score:0(normal) to 9(maximum severity),comprised subscores for SF,RB,ES.higher score=more severe disease activity.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Clinical Remission at Week 12
Percentage of participantsPlaceboEtrasimod 1 mgEtrasimod 2 mg
Percentage of Participants Who Achieved Clinical Remission at Week 1206.726.3
Statistical analysis
  • Placebo vs Etrasimod 1 mg · Difference in percentage: 6.7 · 95% CI -5.96 to 19.29
  • Placebo vs Etrasimod 2 mg · Difference in percentage: 26.3 · 95% CI 6.52 to 46.12
SecondaryPercentage of Participants Who Achieved Endoscopic Improvement at Week 12

Endoscopic improvement was defined as ES \<= 1 (excluding friability). ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]), higher scores = more severity. Modified Mayo score (MMS): measure disease activity for UC, score: 0 (normal) to 9 (maximum severity),and comprised the subscores for SF, RB, ES. Higher score = more severe disease activity.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Endoscopic Improvement at Week 12
Percentage of participantsPlaceboEtrasimod 1 mgEtrasimod 2 mg
Percentage of Participants Who Achieved Endoscopic Improvement at Week 1206.726.3
Statistical analysis
  • Placebo vs Etrasimod 1 mg · Difference in percentage: 6.7 · 95% CI -5.96 to 19.29
  • Placebo vs Etrasimod 2 mg · Difference in percentage: 26.3 · 95% CI 6.52 to 46.12
SecondaryPercentage of Participants Who Achieved Symptomatic Remission at Week 12

Symptomatic remission was defined as SF sub score = 0 (or = 1 with a \>= 1 point decrease from baseline) and RB sub score = 0. SF subscore: reported number of stools in a 24-hour period relative to normal number of stools for that participant in the same period, score ranged from 0 (normal number of stools) to 3 (5 or more stools than normal), higher scores = more severity. RB subscore: reported the most severe amount of blood passed per rectum in a 24-hour period, score ranged from 0 (no blood seen) to 3 (blood alone passes), higher scores = more severity. MMS: measure disease activity for UC, score: 0 (normal) to 9 (maximum severity), and comprised the subscores for SF, RB, ES. Higher score = more severe disease activity.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Symptomatic Remission at Week 12
Percentage of participantsPlaceboEtrasimod 1 mgEtrasimod 2 mg
Percentage of Participants Who Achieved Symptomatic Remission at Week 12020.031.6
Statistical analysis
  • Placebo vs Etrasimod 1 mg · Difference in percentage: 20.0 · 95% CI -0.24 to 40.24
  • Placebo vs Etrasimod 2 mg · Difference in percentage: 31.6 · 95% CI 10.68 to 52.48
SecondaryPercentage of Participants Who Achieved Mucosal Healing at Week 12

Mucosal healing was defined as ES \<= 1 (excluding friability) with histologic remission defined as a Geboes index score \< 2.0). ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]), higher scores = more severity. The Geboes score grading system, was a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicated more severe disease. Modified Mayo score (MMS): measure disease activity for UC, score: 0 (normal) to 9 (maximum severity), comprised subscores for SF, RB, ES. Higher score = more severe disease activity.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Mucosal Healing at Week 12
Percentage of participantsPlaceboEtrasimod 1 mgEtrasimod 2 mg
Percentage of Participants Who Achieved Mucosal Healing at Week 1206.75.3
Statistical analysis
  • Placebo vs Etrasimod 1 mg · Difference in percentage: 6.7 · 95% CI -5.96 to 19.29
  • Placebo vs Etrasimod 2 mg · Difference in percentage: 5.3 · 95% CI -4.78 to 15.30
SecondaryPercentage of Participants Who Achieved Clinical Response at Week 12

Clinical response was defined as a \>= 2-point and \>= 30 percentage (%) decrease from baseline in MMS, and a \>= 1-point decrease from baseline in RB subscore or an absolute RB subscore \<= 1. MMS: measure disease activity for UC, score: 0 (normal) to 9 (maximum severity), and comprised the subscores for SF, RB, ES. Higher score = more severe disease activity. RB subscore: reported the most severe amount of blood passed per rectum in a 24-hour period, score ranged from 0 (no blood seen) to 3 (blood alone passes), higher scores = more severity.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Clinical Response at Week 12
Percentage of participantsPlaceboEtrasimod 1 mgEtrasimod 2 mg
Percentage of Participants Who Achieved Clinical Response at Week 127.133.352.6
Statistical analysis
  • Placebo vs Etrasimod 1 mg · Difference in percentage: 26.2 · 95% CI -1.22 to 53.60
  • Placebo vs Etrasimod 2 mg · Difference in percentage: 45.5 · 95% CI 19.30 to 71.68
SecondaryPercentage of Participants Who Achieved Endoscopic Normalization at Week 12

Endoscopic normalization was defined as ES= 0. ES reported worst appearance of mucosa on flexible sigmoidoscopy or colonoscopy, score ranged from 0 (normal or inactive disease) to 3 (severe disease \[spontaneous bleeding, ulceration\]), higher scores = more severity. MMS: measure disease activity for UC, score: 0 (normal) to 9 (maximum severity), and comprised the subscores for SF, RB, ES. Higher score = more severe disease activity.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Endoscopic Normalization at Week 12
Percentage of participantsPlaceboEtrasimod 1 mgEtrasimod 2 mg
Percentage of Participants Who Achieved Endoscopic Normalization at Week 12000
Other pre-specifiedNumber of Participants With Adverse Events According to Severity

An adverse event was any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. An adverse event was therefore any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Severity was classified using common terminology criteria for adverse events (CTCAE), version 5.0, such as Grade 1 for mild, Grade 2 for moderate, Grade 3 for severe, Grade 4 for life-threatening, Grade 5 for death related to adverse event.

Time frame:
Day 1 of first dose of study treatment up to 4 weeks after administration of the final dose of study treatment (maximum up to 16 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events According to Severity
ParticipantsPlaceboEtrasimod 1 mgEtrasimod 2 mg
Grade15611
Grade 2532
Grade 3000
Grade 4000
Grade 5000

Adverse events

Collected over Day 1 of first dose of study treatment up to 4 weeks after administration of the final dose of study treatment (maximum up to 16 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/18 (0%)0/18 (0%)10/18 (55.6%)
Etrasimod 1 mg0/17 (0%)0/17 (0%)9/17 (52.9%)
Etrasimod 2 mg0/19 (0%)0/19 (0%)13/19 (68.4%)
Most frequent other events
Showing 10 of 43
Most frequent other events
EventPlaceboEtrasimod 1 mgEtrasimod 2 mg
Colitis ulcerativeGastrointestinal disorders3/180/170/19
StomatitisGastrointestinal disorders0/182/170/19
Chronic gastritisGastrointestinal disorders0/181/170/19
NauseaGastrointestinal disorders1/181/170/19
MalaiseGeneral disorders0/181/171/19
Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders0/181/170/19
Neck painMusculoskeletal and connective tissue disorders0/181/170/19
EczemaSkin and subcutaneous tissue disorders0/181/170/19
PruritusSkin and subcutaneous tissue disorders0/181/170/19
RashSkin and subcutaneous tissue disorders0/181/170/19

Baseline characteristics

The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(Years)PlaceboEtrasimod 1 mgEtrasimod 2 mgTotal
Mean38.5 ± 9.2841.6 ± 14.0449.5 ± 11.5543.3 ± 12.45
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEtrasimod 1 mgEtrasimod 2 mgTotal
Female56819
Male13111135
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboEtrasimod 1 mgEtrasimod 2 mgTotal
Hispanic or Latino0000
Not Hispanic or Latino18171954
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboEtrasimod 1 mgEtrasimod 2 mgTotal
American Indian or Alaska Native0000
Asian18171954
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
08

Study locations

80 sites
  • Toyohashi Municipal Hospital
    Toyohashi-shi, Aichi- KEN 441-8570, Japan
  • Aichi Medical University Hospital
    Nagakute, Aichi 480-1195, Japan
  • Kojunkai Daido Clinic
    Nagoya-shi, Aichi 457-8511, Japan
  • Nagoya City University Hospital
    Nagoya-shi, Aichi 467-8602, Japan
  • Fujita Health University Hospital
    Toyoake-City, Aichi 470-1192, Japan
  • Kojunkai Daido Hospital
    Nagoya-shi, Aixhi-ken 457-8511, Japan
  • Hirosaki University Hospital(OCT/PFT/DLCO)
    Hirosaki-shi, Aomori KEN 036-8563, Japan
  • Hirosaki University Hospital
    Hirosaki-shi, Aomori KEN 036-8563, Japan
  • NHO Hirosaki General Medical Center
    Hirosaki-shi, Aomori-ken 036-8545, Japan
  • Tsujinaka Hospital Kashiwanoha
    Kashiwa-shi, Chiba 277-0871, Japan
  • Ishii Eye Clinic
    Nagareyama-shi, Chiba 270-0116, Japan
  • Toho University Sakura Medical Center
    Sakura, Chiba 285-8741, Japan
  • Saiseikai Matsuyama Hospital
    Matsuyama-shi, Ehime 791-8026, Japan
  • Ehime University Hospital
    Toon-shi, Ehime 791-0295, Japan
  • Fukuoka University Hospital
    Fukuoka-shi, Fukuoka 814-0180, Japan
  • Kokura Memorial Hospital
    Kitakyushu-shi, Fukuoka 802-8555, Japan
  • Kitakyushu Municipal Medical Center
    Kitakyushu-shi, Fukuoka 802-8561, Japan
  • Koyanose Eye Clinic
    Kitakyushu-shi, Fukuoka 807-1266, Japan
  • Japan Community Health Care Organization Kyushu Hospital
    Kitakyushu, Fukuoka 806-8501, Japan
  • Kurume University Hospital
    Kurume-shi, Fukuoka 830-0011, Japan
  • Our Lady of the Snow St. Mary's Hospital
    Kurume, Fukuoka 830-8543, Japan
  • Kokura Memorial Hospital
    Kutakyushu-shi, Fukuoka 802-8555, Japan
  • Fukuoka Shinmizumaki Hospital
    Onga-gun, Fukuoka 807-0051, Japan
  • Gifu University Hospital
    Gifu-shi, Gifu-ken 501-1194, Japan
  • SUBARU Health Insurance Society Ota Memorial Hospital
    Ota-shi, Gunma 373-8585, Japan
  • Nakayama EYE Clinic
    Fukuyama-shi, Hiroshima 720-0822, Japan
  • NHO Fukuyama Medical Center
    Fukuyama-shi, Hiroshima 720-8520, Japan
  • Hiroshima University Hospital
    Hiroshima-shi, Hiroshima 734-8551, Japan
  • Asahikawa City Hospital
    Asahikawa-shi, Hokkaido 070-8610, Japan
  • Tokushukai Sapporo Tokushukai Hospital
    Sapporo-shi, Hokkaido 004-0041, Japan
  • Sapporo-Kosei General Hospital
    Sapporo-shi, Hokkaido 060-0033, Japan
  • NHO Mito Medical Center
    Higashiibaraki-gun, Ibaraki 311-3193, Japan
  • Yuai Memorial Hospital
    Koga-shi, Ibaraki 306-0232, Japan
  • Ibaraki Seinan Medical Center Hospital
    Sashima-gun, Ibaraki 306-0433, Japan
  • Matsumoto Eye Clinic
    Toride-shi, Ibaraki 302-0014, Japan
  • Tsuchiura Kyodo General Hospital
    Tsuchiura-shi, Ibaraki 300-0028, Japan
  • NHO Kanazawa Medical Center
    Kanazawa-shi, Ishikawa 920-8650, Japan
  • Kudo Internist Heart Clinic
    Morioka-shi, Iwate-ken 020-0871, Japan
  • Iwate Medical University Uchimaru Medical Center
    Morioka-shi, Iwate 020-8505, Japan
  • Takamatsu Red Cross Hospital
    Takamatsu-shi, Kagawa 760-0017, Japan
  • JA- Kagoshima Koseiren Hospital (PET/DLCO)
    Kagoshima-shi, Kagoshima 890-0062, Japan
  • Clinical Pathology Laboratory (Diagnostick center)
    Kagoshima-shi, Kagoshima 892-0813, Japan
  • Sameshima Eye Clinic (OCT)
    Kagoshima-shi, Kagoshima 892-0825, Japan
  • Sameshima Hospital
    Kagoshima-shi, Kagoshima 892-0846, Japan
  • Sagamihara Kyodo Hospital
    Sagamihara, Kanagawa 252-5188, Japan
  • Social Welfare Organization Imperial Gift Foundation,Inc.Saiseikai Yokohamashi Nanbu Hospital
    Yokohama-shi, Kanagawa 234-0054, Japan
  • NHO Yokohama Medical Center
    Yokohama-shi, Kanagawa 245-8575, Japan
  • Japanese Red Cross Kumamoto Hospital
    Kumamoto-shi, Kumamoto 861-8520, Japan
  • University Hospital Kyoto Prefectural University of Medicine
    Kyoto-shi, Kyoto 602-8566, Japan
  • National Hospital Organization Kyoto Medical Center
    Kyoto-shi, Kyoto 612-8555, Japan
  • Hinaga Nishi Ophthalmology Clinic
    Yokkaichi- Shi, Mie-ken 510-0891, Japan
  • Mie Prefectural General Medical Center
    Yokkaichi-shi, Mie-ken 510-8561, Japan
  • Mie University Hospital
    Tsu-shi, MIE 514-8507, Japan
  • JOHAS Tohoku Rosai Hospital
    Sendai-shi, Miyagi 981-8563, Japan
  • Tohoku University Hospital
    Sendai, Miyagi 980-8574, Japan
  • Nagaoka Red Cross Hospital
    Nagaoka-shi, Niigata 940-2085, Japan
  • Kansai Medical University Hospital
    Hirakata-shi, Osaka 573-1191, Japan
  • Medical Corporation Tokushukai Kishiwada Tokushukai Hospital
    Kishiwada-shi, Osaka 596-0042, Japan
  • Osaka City University Hospital
    Osaka-shi, Osaka 545-8586, Japan
  • Japan Community Health care Organization Osaka Hospital
    Osaka-shi, Osaka 553-0003, Japan
  • Osaka Medical and Pharmaceutical University Hospital
    Takatsuki-City, Osaka 569-8686, Japan
  • Saga University Hospital
    Saga-shi, Saga 849-8501, Japan
  • Japan Community Health care Organization Saitama Medical Center
    Saitama-shi, Saitama-ken 330-0074, Japan
  • Saitama Medical University Hospital
    Iruma-gun, Saitama 350-0495, Japan
  • Shiga University of Medical Science Hospital
    Otsu, Shiga 520-2192, Japan
  • Hamamatsu Medical Centre
    Hamamatsu-shi, Shizuoka-ken 432-8580, Japan
  • Hamamatsu University Hospital
    Hamamatsu-shi, Shizuoka 431-3192, Japan
  • Matsuda Hospital
    Hamamatsu, Shizuoka 432-8061, Japan
  • Tokyo Medical and Dental University Hospital
    Bunkyo-ku, Tokyo 113-8519, Japan
  • Tokai University Hachioji Hospital
    Hachioji, Tokyo 192-0032, Japan
  • Showa General Hospital
    Kodaira-shi, Tokyo 187-8510, Japan
  • Kitasato University Kitasato Institute Hospital
    Minato-ku, Tokyo 108-8642, Japan
  • JCHO Tokyo Yamate Medical Center
    Shinjuku-ku, Tokyo 169-0073, Japan
  • Wakayama Medical University Hospital
    Wakayama-shi, Wakayama 641-8510, Japan
  • Yamanashi Prefectural Central Hospital
    Kofu-shi, Yamanashi 400-8506, Japan
  • Fukushima Medical University Hospital
    Fukushima, 960-1295, Japan
  • Kagoshima University Hospital
    Kagoshima, 890-8520, Japan
  • NHO Osaka National Hospital
    Osaka, 540-0006, Japan
  • Osaka National Hospital Institutional Review Board
    Osaka, 540-0006, Japan
  • Teikyo University Hospital
    Tokyo, 173-8606, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Oct 2023, 24 months.

Results were first posted in Oct 2024, 1 year after primary completion.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 24 months is below that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2021
First posted
Sep 29, 2021
StartActual
Sep 10, 2021
Primary completionActual
Oct 6, 2023
CompletionActual
Oct 6, 2023
Results first posted
Oct 29, 2024
Last update
Oct 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05061446
Lead sponsor
Pfizer
Collaborators
Arena is a wholly owned subsidiary of Pfizer
Responsible party
Sponsor
First posted
Sep 29, 2021
Start date
Sep 10, 2021
Primary completion
Oct 6, 2023
Completion
Oct 6, 2023
Results posted
Oct 29, 2024
Last update
Oct 29, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etrasimod

Start the discussion